Back to Search Start Over

EBV deletions as biomarkers of response to treatment of Chronic Active Epstein Barr Virus

Authors :
Venturini, Cristina
Houldcroft, Charlotte
Lazareva, Arina
Wegner, Fanny
Morfopoulou, Sofia
Amrolia, Persis
Golwala, Zainab
Rao, Anupama
Marks, Stephen
Simmonds, Jacob
Yoshikawa, Tetsushi
Farrell, Paul
Cohen, Jeffrey
Worth, Austen
Breuer, Judith
Venturini, Cristina [0000-0002-4769-7912]
Houldcroft, Charlotte [0000-0002-1833-5285]
Wegner, Fanny [0000-0003-4348-5872]
Morfopoulou, Sofia [0000-0001-8181-4548]
Amrolia, Persis [0000-0003-0480-3911]
Apollo - University of Cambridge Repository
Publication Year :
2020
Publisher :
Cold Spring Harbor Laboratory, 2020.

Abstract

Chronic active Epstein Barr Virus (CAEBV) is a rare condition occurring in previously healthy individuals associated with persistent EBV viraemia, fever, lymphadenopathy and hepatosplenomegaly. Viral deletions have been found in CAEBV and other lymphomas. However, it is unclear how stable these deletions are, whether they are present in different sites and how they evolve overtime. We sequenced fourteen longitudinal blood samples from three European CAEBV patients and compared with CAEBV saliva samples and other sequences from EBV-related conditions. We observed large EBV deletions in blood, but not saliva from CAEBV patients. Deletions were stable over time but were lost following successful treatment. Our results are consistent with the likelihood that certain deletions in the virus from CAEBV patients are associated with the evolution and persistence of haematological clones. We propose that the loss of deletions following successful treatment should be investigated as a potential biomarker to aid CAEBV management.

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....83d3d9765c49c191d3a448c6e9772840